Phase II Study of Gemcitabine and Vinorelbine Combination Chemotherapy in Patients with Non-Small-Cell Lung Cancer Not Responding to Previous Chemotherapy

Yuh Min Chen, Reury Perng Perng, Chia San Lee, Wei Chun Lin, Chun Ming Tsai, Jacqueline Whang-Peng

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Both gemcitabine and vinorelbine are new anticancer drugs that have shown activity in the treatment of chemonaïve non-small-cell lung cancer (NSCLC). Their role in the second-line treatment of NSCLC is less clear. We conducted a phase II study of gemcitabine and vinorelbine combination chemotherapy in patients with NSCLC who had not responded to previous platinum-based chemotherapy, to assess the response and toxicity of this regimen. Seventeen patients were enrolled from September 1998 to February 2001. Treatment consisted of vinorelbine 20 mg/m2 and gemcitabine 800 mg/m 2 intravenous infusion on days 1, 8, and 15 every 4 weeks. Sixty-five cycles of treatment were given, with a median of four cycles. All patients were evaluable for the toxicity profile, and 16 patients were evaluable for the response rate. The major toxicity was myelosuppression. Grade III or IV neutropenia occurred in 9 patients (52.9%) during treatment. Febrile neutropenia occurred in only 1 patient (5.9%). Grade III anemia and thrombocytopenia occurred in two and three patients, respectively. Other toxicities were few and mild in severity. After 2 cycles of treatment, 5 of 16 patients (31.3%) had a partial response (95% CI 8.6-64%). The median time to disease progression was 4.6 months and the median survival was 8.3 months. The 1-year survival rate was 34.3%. In conclusion, gemcitabine and vinorelbine salvage chemotherapy produces a relatively high response rate, low toxicity profile, and good survival in Chinese patients with NSCLC who have not responded to previous platinum-based chemotherapy. Further study is needed to confirm its activity.

Original languageEnglish
Pages (from-to)567-570
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume26
Issue number6
DOIs
Publication statusPublished - Dec 1 2003
Externally publishedYes

Fingerprint

gemcitabine
Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Drug Therapy
Platinum
Therapeutics
vinorelbine
Febrile Neutropenia
Survival
Neutropenia
Intravenous Infusions
Thrombocytopenia

Keywords

  • Gemcitabine
  • Non-small-cell lung cancer
  • Salvage chemotherapy
  • Vinorelbine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase II Study of Gemcitabine and Vinorelbine Combination Chemotherapy in Patients with Non-Small-Cell Lung Cancer Not Responding to Previous Chemotherapy. / Chen, Yuh Min; Perng, Reury Perng; Lee, Chia San; Lin, Wei Chun; Tsai, Chun Ming; Whang-Peng, Jacqueline.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 26, No. 6, 01.12.2003, p. 567-570.

Research output: Contribution to journalArticle

@article{8357a5a5cd4846999063026559817c42,
title = "Phase II Study of Gemcitabine and Vinorelbine Combination Chemotherapy in Patients with Non-Small-Cell Lung Cancer Not Responding to Previous Chemotherapy",
abstract = "Both gemcitabine and vinorelbine are new anticancer drugs that have shown activity in the treatment of chemona{\"i}ve non-small-cell lung cancer (NSCLC). Their role in the second-line treatment of NSCLC is less clear. We conducted a phase II study of gemcitabine and vinorelbine combination chemotherapy in patients with NSCLC who had not responded to previous platinum-based chemotherapy, to assess the response and toxicity of this regimen. Seventeen patients were enrolled from September 1998 to February 2001. Treatment consisted of vinorelbine 20 mg/m2 and gemcitabine 800 mg/m 2 intravenous infusion on days 1, 8, and 15 every 4 weeks. Sixty-five cycles of treatment were given, with a median of four cycles. All patients were evaluable for the toxicity profile, and 16 patients were evaluable for the response rate. The major toxicity was myelosuppression. Grade III or IV neutropenia occurred in 9 patients (52.9{\%}) during treatment. Febrile neutropenia occurred in only 1 patient (5.9{\%}). Grade III anemia and thrombocytopenia occurred in two and three patients, respectively. Other toxicities were few and mild in severity. After 2 cycles of treatment, 5 of 16 patients (31.3{\%}) had a partial response (95{\%} CI 8.6-64{\%}). The median time to disease progression was 4.6 months and the median survival was 8.3 months. The 1-year survival rate was 34.3{\%}. In conclusion, gemcitabine and vinorelbine salvage chemotherapy produces a relatively high response rate, low toxicity profile, and good survival in Chinese patients with NSCLC who have not responded to previous platinum-based chemotherapy. Further study is needed to confirm its activity.",
keywords = "Gemcitabine, Non-small-cell lung cancer, Salvage chemotherapy, Vinorelbine",
author = "Chen, {Yuh Min} and Perng, {Reury Perng} and Lee, {Chia San} and Lin, {Wei Chun} and Tsai, {Chun Ming} and Jacqueline Whang-Peng",
year = "2003",
month = "12",
day = "1",
doi = "10.1097/01.coc.0000045808.39041.49",
language = "English",
volume = "26",
pages = "567--570",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Phase II Study of Gemcitabine and Vinorelbine Combination Chemotherapy in Patients with Non-Small-Cell Lung Cancer Not Responding to Previous Chemotherapy

AU - Chen, Yuh Min

AU - Perng, Reury Perng

AU - Lee, Chia San

AU - Lin, Wei Chun

AU - Tsai, Chun Ming

AU - Whang-Peng, Jacqueline

PY - 2003/12/1

Y1 - 2003/12/1

N2 - Both gemcitabine and vinorelbine are new anticancer drugs that have shown activity in the treatment of chemonaïve non-small-cell lung cancer (NSCLC). Their role in the second-line treatment of NSCLC is less clear. We conducted a phase II study of gemcitabine and vinorelbine combination chemotherapy in patients with NSCLC who had not responded to previous platinum-based chemotherapy, to assess the response and toxicity of this regimen. Seventeen patients were enrolled from September 1998 to February 2001. Treatment consisted of vinorelbine 20 mg/m2 and gemcitabine 800 mg/m 2 intravenous infusion on days 1, 8, and 15 every 4 weeks. Sixty-five cycles of treatment were given, with a median of four cycles. All patients were evaluable for the toxicity profile, and 16 patients were evaluable for the response rate. The major toxicity was myelosuppression. Grade III or IV neutropenia occurred in 9 patients (52.9%) during treatment. Febrile neutropenia occurred in only 1 patient (5.9%). Grade III anemia and thrombocytopenia occurred in two and three patients, respectively. Other toxicities were few and mild in severity. After 2 cycles of treatment, 5 of 16 patients (31.3%) had a partial response (95% CI 8.6-64%). The median time to disease progression was 4.6 months and the median survival was 8.3 months. The 1-year survival rate was 34.3%. In conclusion, gemcitabine and vinorelbine salvage chemotherapy produces a relatively high response rate, low toxicity profile, and good survival in Chinese patients with NSCLC who have not responded to previous platinum-based chemotherapy. Further study is needed to confirm its activity.

AB - Both gemcitabine and vinorelbine are new anticancer drugs that have shown activity in the treatment of chemonaïve non-small-cell lung cancer (NSCLC). Their role in the second-line treatment of NSCLC is less clear. We conducted a phase II study of gemcitabine and vinorelbine combination chemotherapy in patients with NSCLC who had not responded to previous platinum-based chemotherapy, to assess the response and toxicity of this regimen. Seventeen patients were enrolled from September 1998 to February 2001. Treatment consisted of vinorelbine 20 mg/m2 and gemcitabine 800 mg/m 2 intravenous infusion on days 1, 8, and 15 every 4 weeks. Sixty-five cycles of treatment were given, with a median of four cycles. All patients were evaluable for the toxicity profile, and 16 patients were evaluable for the response rate. The major toxicity was myelosuppression. Grade III or IV neutropenia occurred in 9 patients (52.9%) during treatment. Febrile neutropenia occurred in only 1 patient (5.9%). Grade III anemia and thrombocytopenia occurred in two and three patients, respectively. Other toxicities were few and mild in severity. After 2 cycles of treatment, 5 of 16 patients (31.3%) had a partial response (95% CI 8.6-64%). The median time to disease progression was 4.6 months and the median survival was 8.3 months. The 1-year survival rate was 34.3%. In conclusion, gemcitabine and vinorelbine salvage chemotherapy produces a relatively high response rate, low toxicity profile, and good survival in Chinese patients with NSCLC who have not responded to previous platinum-based chemotherapy. Further study is needed to confirm its activity.

KW - Gemcitabine

KW - Non-small-cell lung cancer

KW - Salvage chemotherapy

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0346850879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346850879&partnerID=8YFLogxK

U2 - 10.1097/01.coc.0000045808.39041.49

DO - 10.1097/01.coc.0000045808.39041.49

M3 - Article

C2 - 14663373

AN - SCOPUS:0346850879

VL - 26

SP - 567

EP - 570

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 6

ER -